Home › Bronchopulmonary Dysplasia › NCT06373289

Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants

Target Oxygen Saturation Ranges in Infants With Bronchopulmonary Dysplasia Associated Pulmonary Hypertension

Who can join

1 Month – 5 Months · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Between 22w 0/7d and 31w 6/7d gestation at birth
* Diagnosed with echocardiographic pulmonary hypertension (1) \>20% flow of blood across the PDA from the pulmonary to arterial circulation, (2) end-systolic flattening of the interventricular septum (eccentricity index \>1.3), or (3) right ventricular pressure estimates ≥ 35 mm Hg
* Receiving supplemental oxygen
* Have mature retinas

Exclusion Criteria:

* Major congenital anomalies

About the study

Around 50% of infants born extremely preterm develop a chronic lung disease known as bronchopulmonary dysplasia of which some infants will also develop pulmonary hypertension of which 50% of children will die before the age of 2. Physicians are currently limited in their ability to select the most appropriate oxygen targets that will improve outcomes in infants with this condition. This clinical trial will determine whether using different amounts of oxygen improve outcomes in infants with this disease.

What is being tested

• higher oxygen saturation target using Nellcor pulse oximetry sensors (device)
• lower oxygen saturation target using Nellcor pulse oximetry sensors (device)

Sponsor: University of Alabama at Birmingham · Participants: 39 · Started: Sep 15, 2026

Contact the study team

• Samuel Gentle, MD · Phone: 205-541-2247

Official record on ClinicalTrials.gov — NCT06373289

Locations in the U.S.

Conditions

• Bronchopulmonary Dysplasia
• Pulmonary Hypertension

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.